MTOR and head and neck squamous cell carcinoma: Specifically for therapeutic drugs targeting the mTOR pathway, despite the fact that promising outcomes were achieved using mTOR inhibitors in experimental models and rapamycin showed encouraging result in the adjuvant setting in a HNSCC clinical trial (NCT01195922, Table 2), advanced HNSCC patients may still display unpredictable drug resistance.